Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2006-11-30
2010-12-14
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C514S04400A, C536S022100
Reexamination Certificate
active
07850975
ABSTRACT:
The present invention is related to methods and compositions that are capable of immediately immunizing a human or animal against any molecule or compound. The present invention comprises an immunity linker molecule with at least two sites; (1) a first binding site that binds to an immune system molecule in a human or animal that has been preimmunized against the first binding site, and (2) one or more second binding sites that bind specifically to a desired compound or molecule. The first binding site and the second binding site(s) are linked by a linker portion of the molecule.
REFERENCES:
patent: 4169137 (1979-09-01), Hirschfeld et al.
patent: 4243749 (1981-01-01), Sadeh et al.
patent: 4711955 (1987-12-01), Ward et al.
patent: 4737453 (1988-04-01), Primus
patent: 4940670 (1990-07-01), Rhodes
patent: 5017558 (1991-05-01), Vyas
patent: 5204449 (1993-04-01), Puri
patent: 5378815 (1995-01-01), Krsmanovic et al.
patent: 5475096 (1995-12-01), Gold et al.
patent: 5683867 (1997-11-01), Biesecker et al.
patent: 5869232 (1999-02-01), Sällberg
patent: 6040137 (2000-03-01), Sallberg
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6245895 (2001-06-01), Sallberg
patent: 6248332 (2001-06-01), Romet-Lemonne et al.
patent: 6660842 (2003-12-01), Sallberg
patent: 6933366 (2005-08-01), Sallberg et al.
patent: 7033594 (2006-04-01), Low et al.
patent: 7112328 (2006-09-01), Marinkovich
patent: 7422746 (2008-09-01), Mullis
patent: 2003/0017165 (2003-01-01), Mullis
patent: 2004/0185054 (2004-09-01), Mullis
patent: 2004/0253679 (2004-12-01), Epstein et al.
patent: 2006/0002891 (2006-01-01), Pouletty
patent: 0429816 (1991-05-01), None
patent: WO 92/08491 (1992-05-01), None
patent: WO 95/05454 (1995-02-01), None
patent: WO 95/29938 (1995-11-01), None
patent: WO 97/37690 (1997-10-01), None
patent: WO 01/25416 (2001-04-01), None
patent: WO 01/32207 (2001-05-01), None
patent: WO 01/45734 (2001-06-01), None
patent: WO 2005/079423 (2005-09-01), None
Davis et al, Nucleic Acid Research, vol. 24, No. 4, 702-706, 1996.
Herbert et al (Eds.), Dictionary of Immunology, Third Edition, Blackwell Scientific Publications, 1985, pp. 3-4, 166.
Alexander, H. et al; “Altering the antigenicity of proteins”; Proc. Natl. Acad. Sci. USA, vol. 89, pp. 3352-3356, Apr. 1992.
Ahnert-Hilger, G. et al.; “Monoclonal Antibodies Against Tetanus Toxin and Toxoid”; Med Microbial Immunol; (1983) 172:123-135.
Bruno, John G. et al; “In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection”; Biosensors & Bioelectronics 14 (1999), pp. 457-464.
Carter, J. Mark; “Epitope Mapping of a Protein Using the Geysen (PEPSCAN) Procedure”; Methods in Molecular Biology vol. 36; Peptide Analysis Protocols; pp. 207-223 (1994).
Colas, Pierre et al.; “Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2”; Nature; vol. 380; Apr. 11, 1996; pp. 548-550.
Edmundson, A.B. et al.; “Principles and Pitfalls in Designing Site-Directed Peptide Ligands”; Proteins: Structure, Function and Genetics; 16:246-267 (1993).
Edmundson, Allen B. et al.; “Binding of peptides to proteins: an exercise in molecular design”; 1991 Host-guest molecular interactions: from chemistry to biology. Wiley, Chichester (Ciba Foundation Symposium 158); pp. 213-230.
Finberg, Robert W. et al.; “The Use of Antidiotypic Antibodies as Vaccines Against Infectious Agents”; CRC Critical Reviews in Immunology; vol. 7, Issue 4, (1987); pp. 269-284.
Geysen, H. Mario et al.; “Strategies for epitope analysis using peptide synthesis”; Journal of Immunological Methods, 102 (1987); pp. 259-274.
Geysen, H. Mario et al.; “Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid”; Proc. Natl. Acad. Sci. USA; vol. 81 (Jul. 1984), pp. 3998-4002.
Geysen, H. Mario et al.; “Isotope or mass encoding of combinatorial libraries”; Chemistry & Biology; 1996, vol. 3, No. 8, pp. 679-688.
Glennie, Martin J. et al.; “Preparation and Performance of Bispecific (F(ab′γ)2Antibody Containing Thioether-Linked Fab′γ Fragments”; Journal of Immunology; vol. 139, No. 7, Oct. 1, 1987, pp. 2367-237.
Jayasena, Sumedha D.; “Aptamers: An Emerging Class of Moleculares That Rival Antibodies in Diagnostics”; Clinical Chemistry; vol. 45; No. 9; (1999) pp. 1628-1650.
Ringquist, Steven et al.; “Anti-L-Selectin Oligonucleotide Ligands Recognize CD62L-Positive Leukocytes: Binding Affinity and Specificity of Univalent and Bivalent Ligands”; Cytometry; vol. 33, 1998; pp. 394-405.
Rodda, Stuart J. et al.; “Multipin Technology in the Preparation and Screening of Peptide Libraries”; Australasian Biotechnology 3, pp. 346-347 (1993).
Schultz, Jane S. et al.; “The Combinatorial Library: A Multifunctional Resource”; Biotechnol. Prog., 1996, 12, pp. 729-743.
Smith, George P.; “Surface presentation of protein epitopes using bacteriophage expression systems”; Current Opinion in Biotechnology (1991) vol. 2: pp. 668-673.
Tribbick, Gordon et al.; “Systematic fractionation of serum antibodies using multiple antigen homologous peptides as affinity ligands”; Journal of Immunological Methods, 139, (1991) pp. 155-16.
Valerio, Robert M. et al.; “Multipin peptide synthesis at the micromole scale using 2-hydroxyethyl methacrylate grafted polyethylene supports”; Int. J. Peptide Protein Res. 42, 1993, pp. 1-9.
Wagner, D.S.; “Ratio Encoding Combinatorial Libraries with Stable Isotopes and their Utility in Pharmaceutical Research”; Combinatorial Chemistry & High Throughput Screening, 1998, 1, pp. 143-153.
Weiner, George J. et al.; “Bispecific Anti-Idiotype/Anti-CD3 Antibody Therapy of Murine B Cell Lymphoma”; The Journal of Immunology; vol. 147, No. 11, Dec. 1, 1991, pp. 4035-4044.
Xu, Wei et al.; “Anti-peptide aptamers recognize amino acid sequence and bind a protein epitope”; Proc. Natl. Acad. Sci. USA; vol. 93, Jul. 1996, pp. 7475-7480.
Galili, Uri et al.; “α-Gal and Anti-Gal α1,3 Galactosyltransferase, α-Gal Epitopes, and the Natural Anti-Gal Antibody”; Subcellular Biochemistry; vol. 32, 1999, pp. 1-23.
Conrad, Richard et al.; “In Vitro Selection of Nucleic Acid Aptamers That Bind Proteins”; Methods in Enzymology, vol. 267, 1996, pp. 336-367.
Fitzwater, Tim et al.; “A SELEX Primer”; Methods in Enzymology, vol. 267, 1996, pp. 275-301.
Famulok, M., and Mayer, G.; “Aptamers as Tools in Molecular Biology and Immunology”, Current Topics in Microbiology and Immunology, 1999, vol. 243, pp. 123-135; New York; Springer-Verlag, Inc.
Janczuk, A. et al.; “alpha-Gal Oligosaccharides: Chemistry and Potential Biomedical Application”; Current Medicinal Chemistry; 1999, vol. 6, pp. 155-164.
Office Action for U.S. Appl. No. 10/754,456, pp. 1-8, Apr. 1, 2008.
Altermune Technologies, LLC
Johnson & Associates
Saunders David A
LandOfFree
Chemically programmable immunity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemically programmable immunity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemically programmable immunity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4204422